Nanotechnology at the Metabolic Interface: Emerging Solutions for Obesity-Driven Diabetes
Winniefred Nankya
Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug
ABSTRACT
Obesity and type 2 diabetes (T2D) are increasingly prevalent global health issues, often coexisting as part of a metabolic syndrome characterized by insulin resistance and chronic inflammation. Recent advances in nanotechnology offer innovative solutions to address the complex interplay between these two conditions, particularly at the metabolic interface. Nanomedicine presents novel strategies for improving drug delivery, targeting inflammation, regulating metabolic pathways, and enhancing tissue regeneration. This review explores emerging nano-based solutions that aim to break the vicious cycle of obesity-driven diabetes. By leveraging the unique properties of nanomaterials, such as enhanced bioavailability, tissue-specific targeting, and the ability to modulate cellular signaling, these therapeutic approaches hold the potential to transform the management of obesity-induced metabolic disorders. We discuss the role of nanoparticles, nanocarriers, and nanomaterials in modulating key metabolic processes, such as insulin signaling, lipid metabolism, and adipogenesis. The review also considers the clinical prospects and challenges of translating nanotechnologybased treatments into mainstream healthcare for obesity-driven diabetes, emphasizing the importance of safety, efficacy, and regulatory approval. These emerging solutions hold promise for reshaping the treatment landscape of metabolic diseases and improving patient outcomes on a global scale.
Keywords: Nanomedicine, Obesity, Diabetes, Metabolic Disorders, Drug Delivery.
CITE AS: Winniefred Nankya (2026). Nanotechnology at the Metabolic Interface: Emerging Solutions for Obesity-Driven Diabetes. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):96-101. https://doi.org/10.59298/IDOSRJSR/2026/11.2.96101